Truist Securities Maintains Buy on Insulet, Lowers Price Target to $219

Benzinga Newsdesk www.benzinga.com Negative 70.8%

Neg 70.8% Neu 0% Pos 0%

Truist Securities analyst Richard Newitter maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $219.